Cb21 Pharma

CB21 Pharma leads Europe in science-backed, trusted innovation for accessible CBD healthcare. Our portfolio includes the EU’s only three CE-marked cannabinoid medical devices, setting the standard for regulatory excellence and clinical validation. Our science-backed solutions span Women’s Health, Proctology, Urology, Oral Care, and Mental Well-Being—delivering quality, efficacy, and safety to patients across 27 European markets. We combine deep expertise in EU MDR compliance, GMP-certified manufacturing, and rapid adaptation to evolving pharmacopoeia standards. Our integrated regulatory and IP strategy provides market exclusivity through 2041, offering partners a de-risked, scalable platform for transformative health solutions.